About The Journal
  Aims and Scope
  Editorial Board
  Submit a Manuscript 
  Subscription Information
  Guidelines for Publication
  Ethics
Articles & Issues
  Search
  Issue
  Online First
  KJChE on
For Authors
  Instructions to Authors
  Ethical Responsibilities of
  Authors in KJChE
  Ethics in Publishing
  Peer Review Process
  Author's Checklist
  Copyright Transfer Form
Contact us
 
 
 
Issue
Korean Journal of Chemical Engineering,
Vol.35, No.4, 984-993, 2018
Agomelatine co-crystals with resorcinol and hydroquinone: Preparation and characterization
Lee MJ, Chun NH, Kim HC, Kim MJ, Kim P, Cho MY, Choi GJ
Perovskite type BiFeO3 (BFO) was synthesized by sol-gel auto-combustion method. Synthesized BFO was immobilized on the micro slides glass plates by sol-gel dip-coating method. The sample was characterized by XRD, FESEM, UV-Vis DRS, and BET techniques. The XRD pattern confirmed the perovskite structure, and from the Debye- Scherrer equation the average crystalline size was calculated as 19 nm. The FE-SEM images of prepared BFO showed porous structure with low agglomeration. The band gap energy was calculated about 2.13 eV, and the specific surface area (SSA) of prepared BFO nanostructure was obtained 55.1m2 g-1. The photocatalytic activity of prepared pure and immobilized BFO was investigated in the removal of NOx under UV irradiation, in the batch photoreactor. The effects of operational parameters such as initial concentration of NOx, light intensity and amount of coated photocatalyst, under identical conditions, were investigated. The results showed that the highest conversion of NOx was obtained as 35.83% in the 5 ppm of NOx with 1.2 g immobilized BFO and under 15 W illumination lamp.
Keywords: Co-crystal; Agomelatine; Resorcinol; Hydroquinone; Solubility
[References]
  1. Prohens R, Barbas R, Portell A, Font-Bardia M, Alcobe X, Puigjaner C, Cryst. Growth Des., 16, 1063, 2016
  2. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ, J. Pharm. Sci., 95, 499, 2006
  3. Babu NJ, Nangia A, Cryst. Growth Des., 11, 2662, 2011
  4. Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, Desiraju GR, Dikundwar AG, Dubey R, et al., Cryst. Growth Des., 12, 2147, 2012
  5. US FDA, Guidance for Industry: Regulatory Classification of Pharmaceutical Co-crystals; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM516813.pdf (2016).
  6. US FDA, Guidance for Industry: Regulatory Classification of Pharmaceutical Co-crystals, http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM281764.pdf (2013).
  7. US FDA. Generally Regarded as Safe, http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/.
  8. US FDA. Everything Added to Food Stuff in the United States, http://www.fda.gov/Food/ IngredientsPackagingLabeling/FoodAdditivesIngredients/ucm115326.htm, http://www.accessdata.fda.gov/scripts/fcn/fcnnavigation.cfm?rpt=eafuslisting.
  9. Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB, Mol. Pharm., 4, 386, 2007
  10. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R, Akrami A, Rose M, Surapaneni S, Bostick T, King A, Neervannan S, Ostovic D, Koparkar A, J. Pharm. Sci., 97, 3942, 2008
  11. Hickey MB, Peterson ML, Scoppettuolo LA, Morrisette SL, Vetter A, Guzman H, Remenar JF, Zhang Z, Tawa MD, Haley S, Zaworotko MJ, Almarsson O, Eur. J. Pharm. Biopharm., 67, 112, 2007
  12. Schultheiss N, Newman A, Cryst. Growth Des., 9, 2950, 2009
  13. Lee MJ, Wang IC, Kim MJ, Kim P, Song KH, Chun NH, Park HG, Choi GJ, Korean J. Chem. Eng., 32(9), 1910, 2015
  14. Demyttenaere K, Eur. Neuropsychopharmacol., 21, A703, 2011
  15. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ, Nat. Rev. Drug Discov., 9, 628, 2010
  16. VALDOXAN® - Product Information. http://www.guildlink.com.au/gc/ws/servier/pi.cfm?product= sepvaldx.
  17. Zheng SL, Chen JM, Zhang WX, Lu TB, Cryst. Growth Des., 11, 466, 2011
  18. Zhang Q, Jiang L, Mei X, Pharm. Dev. Technol., 21, 196, 2016
  19. Yan Y, Chen JM, Geng N, Lu TB, Cryst. Growth Des., 12, 2226, 2012
  20. Yin HS, Zhang QM, Zhou YL, Ma QA, Liu T, Zhu LS, Ai SY, Electrochim. Acta, 56(6), 2748, 2011
  21. Cherukuvada S, Nangia A, Chem. Commun., 50, 906, 2014
  22. Tata J, Scalarone D, Lazzari M, Chiantore O, Eur. Polym. J., 45, 2520, 2009
  23. Lu E, Rodriguez-Hornedo N, Suryanarayanan R, CrystEngComm., 10, 665, 2008
  24. Yamashita H, Hirakura Y, Yuda M, Teramura T, Terada K, Pharm. Res., 30, 70, 2013
  25. Yamashita H, Hirakura Y, Yuda M, Terada K, Pharm. Res., 31, 1946, 2014
  26. Zhou Z, Chan HM, Sung HHY, Tong HHY, Zheng Y, Pharm. Res., 33, 1030, 2016
  27. Friscic T, Jones W, Cryst. Growth Des., 9, 1621, 2009
  28. Chadwick K, Davey R, Cross W, CrystEngComm., 9, 732, 2007
  29. Tamura R, Miyata M, Advances in organic crystal chemistry: Comprehensive reviews, Springer Japan, Tokyo (2015).
  30. Kaur R, Row TNG, Cryst. Growth Des., 12, 2744, 2012
  31. Kaur R, Cherukuvada S, Managutti PB, Row TNG, CrystEngComm., 18, 3191, 2016
  32. Alhalaweh A, George S, Basavoju A, Childs SL, Rizvic SAA, Velaga SP, CrystEngComm., 14, 5078, 2012
  33. Elbagerma MA, Edwards HGM, Munshi T, Scowen IJ, CrystEngComm., 13, 1877, 2011
  34. Mayo DW, Miller FA, Hannah RW, Course notes on the interpretation of infrared and Raman spectra, Wiley, New Jersey (2004).
  35. Socrates G. Infrared and Raman characteristic group frequencies: Tables and charts, 3rd Ed., Wiley, New York (2001).
  36. Good DJ, Rodriguez-Hornedo N, Cryst. Growth Des., 9, 2252, 2009
  37. DrugBank - Agomelatine, https://www.drugbank.ca/drugs/DB06594.
  38. Du W, Zhou Y, Gong Y, Zhao C, Asian J. Pharm. Sci., 8, 181, 2013
  39. Saha R, Sengupta S, Dey SK, Steele IM, Bhattacharyya A, Biswas S, Kumar S, RSC Adv., 4, 49070, 2014
[Cited By]
  1. Hyun KH, Kang SY, Kwon YC, Korean Journal of Chemical Engineering, 36(3), 500, 2019
참고문헌정보(참고문헌, 인용문헌)는 화학공학소재연구정보센터에 의해 제공되고 있습니다.